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Multiple use of dialyzers: Safety and efficacy. The practice of
multiple use of dialyzers was examined over a 15-month period
on all 104 patients in a chronic maintenance hemodialysis
facility. A computerized medical information system permitted
analysis of the incidence of events in over 10,000 successive
hemodialyses. It also allowed analysis of the events in 27
patients dialyzed for a total of 655 months successively in two
units practicing single and multiple dialyzer use. The incidence
of complications during dialysis, of complications that might be
related to infection, and the rate of hospitalization was not
greater when the 27 patients were dialyzed in the unit practicing
multiple use as compared with the rates in the unit practicing
single use. Events possibly associated with infection did not
occur more frequently during dialyses in which the dialyzer had
been used between 2 and 20 times than they did with the initial
use of the dialyzer. With successive dialyzer use, there was no
significant change in the ability to remove fluid or in the
dialysance of urea and creatinine. The neutropenia that charac-
teristically occurs early in dialysis was substantially less with
reused dialyzers than with their initial use. Under the operating
conditions described, we conclude that multiple dialyzer use
over a 15-month period is safe, efficacious, and is not associated
with an increased rate of infection, of morbidity from any cause,
or of mortality.
Utilisation multiple des dialyseurs: Sécurité et efficacité. L'utili-
sation multiple des dialyseurs a èté étudiée sur une période de 15
mois chez l'ensemble des 104 malades d'un centre d'hCmodia-
lyse. Un système de dossier medical informatisé a permis
l'analyse de la frequence d'évènements au cours de plus de
10.000 hemodialyses. II a aussi permis l'analyse des évènements
chez 27 malades dialyses pendant un total de 655 mois succes-
sivement dans deux centres dont l'un utilisait les dialyseurs de
facon unique et l'autre de facon multiple. La frequence des
complications au cours de Ia dialyse, ou des complications qui
peuvent ètre en rapport avec l'infection, et Ia frequence des
hospitalisations n'a pas été plus grande quand les 27 malades ont
èté dialyses dans Ic centre utilisant a plusieurs reprises les
dialyseurs que dans l'autre. Les évènements en rapport possible
avec l'infection ne sont pas survenus plus souvent au cours des
dialyses pour lesquelles Ic dialyseur avait déjà servi de 2 a 20 fois
qu'au cours de celles oU le dialyseur était utilisé pour Ia premiere
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fois. II n'a pas été observe de modification de Ia possibilité de
soustraire de l'eau ou de Ia dialysance de l'urée et de La
créatinine. La neutropénie qui survient tot au cours de la dialyse
était très atténuée quand les dialyseurs étaient réemployés. Dans
les conditions décrites nous concluons que l'utilisation multiple
des dialyseurs offre des garanties de sécurité et d'efficacité et
n'est pas associée a une augmentation de fréquence de l'infec-
tion, d'états morbides ou de Ia mortalité.
Patients with chronic renal failure have been
treated by hemodialysis for almost two decades,
and the treatment of large numbers of patients has
been the practice in many countries for about 10
years or more. Many variables enter into treatment
programs. These patients are in a chronic, relatively
stable state; changes in their clinical status occur
both acutely and over periods of many months and
years. The large amount of data that accrue in these
patients has made it difficult to assess the efficacy of
treatment and the individual parameters that con-
tribute to this.
In this paper, we examine one such variable, the
practice of reusing dialyzers. The study was possi-
ble because a structured medical record and com-
puterized information system was in use. This per-
mitted (1) comparison of the incidence of events on
first and subsequent use of dialyzers, (2) compari-
son of the incidence of events in the same patients
dialyzed long-term in a unit practicing reuse with
those in a unit not practicing reuse; and (3) easy
assessment of the rates of occurrence of major
complications.
Methods
Patients. Patients had been selected for treatment
by hemodialysis by a Selection Committee at the
University of Cincinnati Medical Center. Liberal
selection criteria were used.
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The study was done in Dialysis Clinic-Cincinnati,
a "free-standing" dialysis unit that provides hemo-
dialysis services for patients on chronic mainte-
nance hemodialysis and that is affiliated with the
University of Cincinnati Medical Center. During
the period of study, all patients were treated by the
same physicians in the hospital (UCMC) and in the
free-standing dialysis center (DCC). The Dialysis
Clinic opened in July 1977, and initially only pa-
tients without any significant medical problems
were transferred from the hospital to the limited-
care setting. When the study was started in July
1978, virtually all patients requiring chronic mainte-
nance dialysis were treated in the limited-care unit,
with 104 patients treated one or more times during
the 15-month period. When the study concluded on
September 30, 1979, 80 patients were being treated
by chronic maintenance hemodialysis. Of these, 4
were in the hospital unit, and the remaining 76
(95%) at DCC. In general, patients were transferred
from the hospital to DCC after an initial stabilizing
period.
Method of hemodialysis. Single-pass, individual
dialysate-delivery systems (Cobe Centry II and
Extracorporeal Systems) were used. Except for a
few treatments, only three types of dialyzer were in
use—C-DAK 1.3 m2, C-DAK 1.8 m2, and C-DAK
3500 (all manufactured by Cordis Dow). The dialy-
sate provided a final concentration of: sodium, 135
mEq/liter; potassium 2.0 mEq/liter; calcium, 3.5
mEq/liter; magnesium, 1.5 mEq/liter; chloride, 107
mEq/liter; acetate, 35 mEq/liter; and dextrose, 200
mg/dl. Lower or higher potassium concentrations
on occasion were used, respectively, in patients
hyperkalemic or digitalized. Vascular access was
provided by a primary internal arteriovenous fistula
or by a polytetrafluoroethylene graft (Impragraft®
or Gortex Graft®), Eleven patients were dialyzed
twice weekly and ninety-three were dialyzed thrice
weekly, with the duration of dialysis varying be-
tween 9 and 12 hr/week. Sixty-three patients were
dialyzed with the C-DAK 1.8 m2, forty-one with the
C-DAK 1.3 m2 dialyzer, and sixteen with both dialyz-
ers during the period of study. The C-DAK 3500 was
used occasionally when ultrafiltration greater than the
capacity of the regular dialyzer was needed.
The dialysis prescription was determined by the
patient's size and the ultrafiltration capacity re-
quired, and was that designed to maintain the
predialysis serum urea nitrogen level at 80 to 90
mg/dl. The duration of dialysis was not changed at
individual dialyses to allow for greater ultrafiltra-
tion or dialysis. The transmembrane pressure re-
quired to achieve a desired ultrafiltration rate was
calculated from the ultrafiltration index supplied by
the manufacturer.
Antiplatelet agents were given for clotting epi-
sodes or poor flow in the arteriovenous fistulae to
28 patients throughout, to 4 patients at some time,
and to 72 patients at no time during the course of the
study. All patients received iron, folate, and multi-
vitamin supplements.
Heparin was administered as a predialysis bolus
of 2500 to 3000 U. Heparinization was monitored
with Lee White clotting times, which were main-
tained at greater than 30 mm during most of the
dialysis with infusion rates of between 500 to 3,000
U/hr. Heparin infusion was discontinued in the last
hour of hemodialysis.
Hepatitis B surveillance and prevention. Hepati-
tis B surface antigen (HBsAg) was measured by
radioimmunoassay monthly in all patients and ev-
ery 6 months in staff. Staff exposed to needle sticks
were monitored monthly. Dialyzers were used once
only in patients who were or became HBsAg-
positive. Hyperimmune gamma globulin was used
in 2 staff members exposed to an HBsAG-positive
patient.
Data recording and the computerized medical
record. A computerized medical information sys-
tem has been used since March 1976 and throughout
the period of study [1]. The hemodialysis record
consists of a single page printed on both sides. It
contains a flow sheet, all important information
such as blood pressure, pulse, temperature, and
weight obtained prior to and at the conclusion of
dialysis, and a summary of the major events and of
all complications that occur during the dialysis. At
the conclusion of each dialysis, these data are
entered directly from the flow sheet into the com-
puter at a terminal in the nursing station. An audit
program permits verification of all data entered.
The stored data can be recalled at will in a mode
useful for day-to-day patient management. Any
errors of entry can be checked in the data display
mode. The display mode was used to estimate the
incidence of various events during dialysis.
The computer program permits recall of data that
accrue relatively infrequently over long periods of
time, without interference from data that occur
more frequently. Monthly laboratory data, entered
into the computer when the test results are re-
turned, are available for recall instantaneously
without interference from the daily data.
For purposes of this study, fever was recorded as
a symptom that was elicited at the end of each
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dialysis. Hypotension was defined as a systolic
blood pressure <100 mm Hg. Nausea and vomiting
and tenderness or discharge over the fistula or graft
were recorded at each dialysis. Symptoms such as
cramps, chills, sweating, respiratory distress, and
chest pain were elicited and recorded prospectively
with each dialysis.
Method of dialyzer reuse. The method of dialyzer
reuse, adapted from Hirsch, Girst, and Crouch [21,
makes use of the principle of reverse ultrafiltration
by using positive pressure in the dialysate compart-
ment of the hollow-fiber dialyzer (full details are
given in the Appendix). Reverse osmosis water at a
pressure of 15 pounds/square inch and at 36.7 to
37.2° C is circulated through the blood compartment
and subsequently through the dialysate compart-
ment of the dialyzer. The dialyzer is tested for
residual volume, a negative pressure of 300 mm Hg
is applied to test fiber integrity, and it is then filled
with 1.5% formaldehyde by releasing a clamp in this
vacuum circuit. Before the next dialysis, the dialyz-
er is rinsed with 200 cc of normal saline. To clear
residual formaldehyde, the dialysate is circulated
for 20 mm. It is then tested for residual formalde-
hyde by Deniges's method [31, which uses Schiff's
reagent and has a limit of detection of 0.5 pg/ml.
Dialysis was not initiated until all traces of formal-
dehyde were absent. Blood lines were not reused.
Dialyzers were discarded if the residual volume
was <80% of the original (as specified by the
manufacturer), if the pressure tests failed, or if the
dialyzer looked aesthetically displeasing. The qual-
ity of the dialyzers was monitored by volume and
negative pressure tests as well as by a random, at
least once monthly, culture of the saline effluent
displaced by the blood entering the extracorporeal
circuit. This was done, by a microbiology-trained
technician, with a "clean-catch" technique after
the first 10 ml exiting the venous line was discarded.
The sample was refrigerated at 4° C until plated on
standard agar-pour Petri dishes and incubated at 35°
C for 48 hours. Any visible growth was noted. This
technique was practiced over the last 9 months of
study. Growth was observed in 11 of 478 samples.
In all 11, the collection had been made by a nurse or
patient care technician rather than by the microbi-
ology-trained technician. Subsequent cultures from
the same dialyzers were sterile. On the 11 occasions
on which positive cultures were obtained, no symp-
toms suggesting contamination occurred during
dialysis. Specifically, there was no fever, no sweat-
ing, no chills, and the postdialysis temperature was
normal. The positive cultures therefore appeared to
be due to contamination during collection.
Discarding of dialyzers. During the course of the
study, 1,277 dialyzers were discarded: in 52.4%
because the fiber volume was too low; 12.1% for
aesthetic reasons; 11.6% because the seal on the
cap or casing was broken; 6.9% for a blood leak;
2.7% because the dialyzer failed the negative pres-
sure test; and 2.4% because it was clotted. Also,
5.5% were arbitrarily discarded after 20 uses, and
4.1% were discarded because another dialyzer was
prescribed or because the patient was dialyzed
temporarily in hospital.
Dialysance in vivo. This was measured at blood
and dialysate flows of 200 and 500 mI/mm, respec-
tively. Pump speed was calibrated by bubble times
prior to each determination. Total transmembrane
pressure was fixed at 150 mm Hg. Simultaneous
arterial and venous samples were drawn 15 mm
after a steady state was attained at the end of the
first hour of hemodialysis. The samples were ana-
lyzed for urea and creatinine. When the blood flow
was not exactly 200 ml/min, the value for dialysance
was normalized to a blood flow of 200 ml/min.
Laboratory methods. Routine methods in the
standard clinical laboratories were used. Enzyme
levels were measured kinetically. Serum transferrin
levels were measured by radial immunodiffusion
t141. Bone density was assayed by radiographic
absorptiometry 5].
Results
We studied 104 patients, of whom 44 were males
and 60 females. In age, 20 were 29 years; 31 were
30 to 49 years; 31 were 50 to 59 years; and 22 were
60 years. Of these patients, 18 had diabetes melli-
tus; 11 were insulin dependent. At the conclusion of
the study, the total duration of treatment by hemo-
dialysis (or by hemodialysis and transplantation)
was <6 months in 5 patients; 6 to 12 months in 24,
12 to 24 months in 29, and >24 months in 46. The
number of months of treatment analyzed for each
patient was: for 15 patients <3 months; for 18
patients, 4 to 6 months; for 20 patients, 7 to 9
months; for 17 patients, 10 to 14 months; and for 34
patients, 15 months. When hemodialysis first com-
menced, mean serum creatinine was 14.6 mg/dl and
it was >8 mg/dl in all but 5 patients.
During the 15 months of study, an average of 6.74
uses was obtained per dialyzer (Fig. 1). Three
patients who developed hepatitis B antigenemia and
two in home training were dialyzed with a new
dialyzer on each occasion. When these were ex-
cluded, an average of 7.40 uses was obtained per
dialyzer.
Fig. 1. Average numbers of dialyzer uses per pa-
tient.
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An adverse effect of dialyzer reuse might be an
increased incidence of infection. To test this hy-
pothesis, we compared certain findings in 27 pa-
tients dialyzed at the unit practicing reuse (DCC)
for a total period of 334 patient months, and dia-
lyzed previously in a unit that did not practice reuse
(UCMC) for a comparable earlier period totalling
321 months (Table 1).1 Most findings that might be
associated with infection occurred less frequently
during the period in which dialyzers were reused.
To further test the hypothesis that dialyzer reuse
led to infection, we assessed the incidence of the
same findings when the dialyzer was used for the
first time (N = 1492) or was reused (N = 8559) in
the facility practicing reuse (Table 2). The incidence
of fever, chills, and sweating was the same in both
groups (P> 0.3). Signs that might suggest infection
or inflammation over the fistula sites or graft were
uncommon in both groups. Chest pain was less
frequent during reuse than it was during first dia-
lyzer use (x2 = 5.43; P < 0.02).
As an internal control for findings possibly asso-
ciated with infection, the incidence of hypotension,
'This control period was counted, for each patient, for a
comparable number of months, and was for the last consecutive
such number immediately prior to transfer to DCC. The unstable
period during the initial months of dialysis was excluded, so that
the control period at UCMC specifically excluded the first 3
months after hemodialysis commenced. In fact, at the beginning
of the period used as a control, 6 patients had been dialyzed for 3
to 6 months, three for 6 to 12 months, and the remaining 18 for
>12 months. The method and duration of dialysis was not
different at the two centers. Drake-Willock and Cobe Centry II
proportioning systems, C-DAK 1.8 m2 and C-DAK 1.3 m2, and
Hemaclear (Medical, Inc.) dialyzers were used.
of nausea and vomiting, and of cramps was ana-
lyzed. Hypotension and nausea and vomiting oc-
curred less frequently (P < 0.001) in the dialysis
unit practicing reuse (Table 1); in that unit these
symptoms occurred with equal frequency when
new dialyzers or reused dialyzers were used (Table
2). The differences between the results in the two
units could be due to differences in technique, but
dialyzer reuse itself was not associated with an
adverse effect. Cramps occurred with equal fre-
quency in the two units (Table 1), but in the unit
practicing reuse they were less frequent (x2= 11.54;
P < 0.001) with dialyzer reuse (Table 2).
If dialyzer reuse led to infection, it might be
expected to result in an increased rate of admission
to hospital. Excluding only those admissions when
the patient received a kidney transplant, the num-
ber of hospital admissions and the number of days
in hospital are summarized in Tables 3 and 4. For
problems that appeared to be related or attributable
to renal failure and dialysis, the patients spent an
average of 0.57 days/month in the hospital; for
problems that were not dialysis-related, the rate
was 0.53 days/month. In patients with diabetes
mellitus, the rate was 1.52 days/month; in nondia-
betics, 1.04 days/month. To evaluate this further,
we compared the rate of hospitalization of 27 pa-
tients occurring during the 15-month reuse period
with that of the same patients during the compara-
ble earlier period in the unit not reusing dialyzers
(Table 5). For these 27 patients, the rate of hospital-
ization was not greater when they were treated in
the facility practicing reuse.
Another potential hazard of dialyzer reuse might
be an increase in transmission of hepatitis. In our
4
No. of dialyzer uses
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Table 1. Incidence of selected findings occurring during hemodialysis in 27 patients dialyzed for comparable periods of time in two
facilities, only one of which was reusing dialyzers
Facility using Facility reusing
dialyzer once dialyzers
(N = 3231) (N = 3892)
Event occurring during hemodialysis no. % no. % x2 P
Fever recorded by nurse
Temperature at end of dialysis 37.8 C
Chills
Sweating
Respiratory distress
Chest pain
Tenderness over fistula/graft
Discharge or infection of fistula/graft
Associated with infection
25 0.77 9 0.23
64 3.01 11 0.28
16 0.50 14 0.36
13 0.40 0 0
12 0.37 0 0
82 2.54 63 1.62
41 1.27 27 0.69
31 0.96 32 0.82
9.83
76.6
0.48
13.56
12.35
7.03
5.58
0.24
<0.01
<0.001
>0.4
<0.001
<0.001
<0.01
<0.02
>0.5
Hypotension
Nausea/vomiting
Cramps
Presumably not associated with infection
841 26.03 637 16.37
367 11.36 134 3.44
602 18.63 742 19.06
99.64
167.96
0.19
<0.001
<0.001
>0.5
a Data on this finding were not computerized until October 1976. The postdialysis temperature was available for analysis in 2123
dialyses.
Table 2. Incidence of selected findings occurring during hemodialysis in 10,051 successive hemodialysis treatments in a facility
practicing dialyzer reuse
Second &
First dialyzer use subsequent dialyzer
(N = 1492) use (N = 8559)
Event occurring during hemodialysis no. % no. % x2 P
Fever recorded by nurse
Possibly associated with infection
1 0.07 17 0.19 0.60 >0.3
Temperature at end of dialysis > 37.8a C 5 0.34 48 0.56 0.84 >0.3
Chills 8 0.54 36 i.42 0.17 >0.5
Sweating 2 0.13 9 0.11 0.01 >0.8
Respiratory distress 0 0 0 0
29 1.94 100 1.17
0
Chest pain 5.43 <0.02
Tenderness over fistula/graft 12 0.80 37 0.43 2.90 >0.05
Discharge or infection of fistula/graft 3 0.20 27 0.31 0.24 >0.5
Hypotension
Presumably not associated with infection
298 19.97 1576 18.41 1.94 >0.1
Nausea/vomiting 85 5.70 454 5.30 0.31 >0.5
Cramps 270 18.10 1253 14.63 11.54 <0.001
patient population (Table 6), the incidence of hepa-
titis B surface antigenemia was low (6). The inci-
dence of non-A-non-B hepatitis, considered to be
present when the serum alanine aminotransferase
was elevated on two successive occasions to a level
twice the upper limit of normal or greater
(Schreeder MT, personal communication), was
low. When the data on the 27 patients studied in
both dialysis units were compared, the incidence of
both types of hepatitis was extremely low. One
patient developed HBsAg and one non-A-non-B
hepatitis during the period of dialysis in the UCMC
unit. One developed HBsAg and two non-A-non-B
hepatitis during the period of dialysis in the DCC
facility practicing reuse. Fifty-four nurses, techni-
cians, and ancillary personnel were employed at
DCC during the period of study. None developed a
positive HBsAg or hepatitis. Since the study con-
cluded, antibody to HBsAg has been detected in the
serum of two patient-care personnel. Neither had a
positive HBsAg or clinibal hepatitis.
Another potential disadvantage of dialyzet reuse
is a decreased capacity for ultrafiltration or de-
creased dialysance. To assess the efficiency of the
dialyzer in removing fluid under day-to-day operat-
ing conditions, the average weight change with each
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Table 3. Admissions to hospital during 958 patient months of dialysis in a facility practicing reuse
Major cause of
admission to hospital
No. of patients No. of
admitted admissions
Total
days in
hospital
No. of hospital
days per patient
month of dialysis
Hemodialysis related
Fistulalgraft clotting or revision 18 21 98 0.1
Fistula/graft infection 3 5 59 0.06
Other infections 3 5 16 0.02
Hepatitis 0 0 0 0
Pericarditis/Effusion 4 5 81 0.09
Fluid overload-pulmonary edema 10 11 63 0.07
Actual/suspected myocardial
infarction 4 8 59 0.06
Hyperkalemia 1 1 2 0.002
Parathyroidectomy 3 3 33 0.04
Other 15 19 138 0.15
Diabetes control
Not related to dialysis
2 2 13 0.01
Pretransplant splenectomy,
nephrectomy; transplant
nephrectomy 7 8 83 0.09
Urinary tract problems 3 4 67 0.07
Other 16 24 345 0.37
Total 89 116 1057 1.10
Table 4. Admissions of diabetics and nondiabetics to hospital during 958 patient months of dialysis in a facility practicing reuse
No. of hospital
days per
No. of Months on Days in patient month
patients hemodialysis hospital of dialysis
Diabetics 18 159.7 242 1.52
Nondiabetics 86 785.7 815 1.04
Table S. Admissions to hospital for 27 patients dialyzed for comparable periods in two facilities, one reusing and the other not
reusing dialyzers
No. of
patients
Months on
hemodialysis
Days in hospital per patient
month of dialysis
Dialysis
related
Not related
to dialysis Total
Facility using dialyzer once 27 320.6 0.89 0.43 1.32
Facility reusing dialyzers 27 334.2 0.48 0.48 0.96
Table 6. Incidence of hepatitis B and of non-A non-B hepatitis
during 958 patient months of dialysis in a facility reusing
dialyzers
No. of
patients with
hepatitis
conversion
No. of
conversions per
patient year
Heptatitis B
Non-A non-B hepatitis
3
&'
0.0375
0.075
a All three converted within 90 days of blood transfusion. One
was receiving blood regularly on hemodialysis; in the other two,
blood was given in hospital during surgical procedures.b Five of the six converted within 90 days of blood transfusion;
in three the transfusions were administered in hospital.
dialyzer use was calculated on six successive dia-
lyzers. The results in 15 patients are illustrated in
Table 7. By these operational criteria, the ability of
the dialyzer to remove fluid during dialysis, with
comparable dialysis duration and transmembrane
pressure, did not decrease with increasing use. In
vivo dialysance of creatinine and urea was deter-
mined for 16 C-DAK 1.8 m2 dialyzers and for 6 C-
DAK 1.3 m2 dialyzers during the initial dialysis and
every third dialyzer use thereafter (Table 8). Dialy-
sance of urea and creatinine did not change with
multiple use.
734 Kant et a!
Table 7. Fluid removal during the first and subsequent uses of Cordis-Dow hollow-fiber dialyzers
First use
kg/100 mm Hg TMP
Subsequent use
2 3 4 5 6 7 8
% of value in 1st use
-________________
0.53 0.10(N = 15)
100.0 20.6(N = 15)
97.0 19.6(N = 15)
94.0
(N
17.0 91.0 13.5 95.0 20.1
15) (N = 14) (N = 14)
92.0 20.1(N = 12)
107.0 26.1
(N 12)
a Values are the means 1 SD.
Table 8. In vivo dialysance normalized to a blood flow rate of 200 mI/mm for the first and subsequent use of the Cordis-Dow 1.8 m2
and 1.3 m2 hollow-fiber dialyzersa
Substance dialyzed Type of dialyzer
First use
mi/mm
Subsequent use
3 6 9 12
% of value in 1st use
Urea C-DAK 1.8 m2 173.1 6.8(N = 16)
100.1(N =
4.6
22)
101.0 5.4 98.4(N = 21) (N =
4.2
l3)
98.0 3.8(N = 9)
C-DAK 1.3 m2 148.9 6.4(N= 6)
Creatinine C-DAK 1.8 m2 145.9 13.5
(N = 16)
103.5(N = 11.722)
100.5 1l.4 100.3
(N = 21) (N =
11.7
13)
99.2 12.2(N = 9)
C-DAK 1.3 m2 111.9 12.7(N= 6)
a Values are the means SEM.
The reasons why treatment at DCC was stopped
before completion of this study are summarized in
Table 9. Twelve patients received a transplant, four
were on home dialysis, two were being dialyzed in
another city. Only one returned to dialysis in the
hospital setting during the 958 patient months of the
study. Nine patients died, seven of myocardial
infarction or other presumed cardiac causes.
Another measure of adequacy of dialysis is as-
sumed to be the levels of several biochemical
parameters that reflect protein intake and catabo-
lism, anemia, and calcium and phosphate metabo-
lism. As yet, we know of no norms for these
findings in dialysis units, whatever their mode of
practice. Some of the findings in the last 3 months
are summarized in Figs. 2 and 3, and the change
over the period of study in Table 10. The levels of
serum creatinine, urea nitrogen, and hemotocrit did
not change significantly (only 16 patients, 6 of
whom were anephric, were transfused more than
once). Serum calcium, phosphorus, and alkaline
phosphatase levels were significantly lower at the
end of the period of study.
Serum transferrin values were significantly less
than normal but equal to or slightly higher than
Table 9. Reasons why treatment at dialysis clinic was stopped
before completion of the study
No. of patients
Received a kidney transplant 12
Dialysis in the home 4
Moved to another city 2
Dialysis in the outpatient hospital setting I
Deaths 9
Causes of death: myocardial infarction or other presumed
cardiac cause, 7 patients; withdrawal from dialysis, 1 patient;
systemic lupus erythematosus, 1 patient.
those previously published for patients in renal
failure [4]. Bone density, determined by radiograph-
ic absorptiometry [5], was slightly decreased as
compared with age-matched controls, but compara-
ble to that in two other dialysis units (Colbert C,
personal communication).
Neutropenia has been reported within the first 30
mm after starting hemodialysis with certain types of
dialyzers, including dialyzers such as the C-DAK
1.3 and C-DAK 1.8 manufactured with regenerated
cellulose [7], which has been shown to be associat-
ed with complement activation by the cellulosic
component of the membrane [8]. Varying effects of
0
0.
0
C0C00
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reuse on neutropenia have been reported [9—111.
Total and differential leukocyte counts were, there-
fore, done in seven patients during the first five
dialyzer uses with C-DAK 1.3 and C-DAK 1.8
dialyzers (Fig. 4). A high degree of neutropenia was
observed with the first dialyzer use, and much less
during the second to fifth uses.
Discussion
Dialyzer reuse has been practiced since first
described by Shaldon [12]. Methods used to clean
and sterilize the dialyzer vary. With dialyzer reuse,
the dialysance of small mOlecules, for example,
urea and creatinine, has been reported to decline [9,
13, 141 or to be unaltered [15—17]. The diálysance of
middle molecules seems to be unchanged [181.
Studies of dialysance and reuse are difficult to
compare, for various types of dialyzers have been
sterilized by various methods.
Most studies have been concerned with in vitro
and in vivo methods to compare biocompatibility of
reused and new dialyzers. Either no effect or slight-
ly deleterious effects of dialyzer reuse have been
reported on in vivo biochemical values and on in
vitro dialysance. Most such studies have been
short-term. In the present study, both immediate
and long-term observations are reported for the
entire population of an outpatient dialysis facility.
Short and long-term comparisons were also made in
a subset of these patients dialyzed in two centers,
one of which was reusing, the other not reusing
dialyzers. The data show no significant adverse
short-term effects on in vivo dialysance of urea and
creatinine, and no decreased ability to remove fluid
under operational conditions. They clearly show
that, under the conditions of this study, dialyzer
reuse was not associated with an increased inci-
dence of infection or of hepatitis. The rate of
hospitalization for all causes compares favorably
with published figures of 3 and 1.75 days/month for
patients with and without diabetes [191, and is
similar to that reported by Avram [20]. Mortality
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Appendix A
Method of dialyzer reuse
(1) At the conclusion of dialysis, blood is returned to the patient
with a 400- to 500-mI saline rinse.
(2) The blood compartment is rinsed with reverse osmosis water
till the effluent is clear.
(3) The arterial and venous headers are removed and the reverse
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during the study period was 11.26%/year, which is
comparable to the figure of 13.5%/year in stable
patients under 60 years of age without diabetes
reported by Shapiro, Leonard, and Comty [19], and
to the 14%/year in Avram's series [20]. A recent
British report of patient mortality in units reusing
dialyzers [211 supports the conclusion that there is
no increase in mortality with the practice of multi-
ple dialyzer use. There appear to be no long-term
adverse metabolic effects. The significant decrease
in hemodialysis neutropenia and the lower inci-
dence of chest pain and of cramps may represent
some advantages.
Finally, the reuse of dialyzers effects consider-
able reduction in cost. The calculated cost for the
single use of each dialyzer was $24.15; that for each
use of the multiply used dialyzer was $6.85.0
I I I I0 5 15 30
Time, mm
60
Fig. 4. Circulating neutrophils (expressed as a percentage of the
initial value) in 7 patients during the first 5 dialyzer uses,
Differences from the values obtained in the first dialysis were
examined with the paired t test and are expressed as: < 0.05,
and ** < 0.01.
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Table 10. Results of certain measurements at the beginning and at the end of the study period in 56 patients
Test
Mean value
in the first
3 months
Mean difference°
(first 3 months minus
last 3 months) t P
Hematocrit, %
Serum creatinine, mg/kg body wt
Serum urea nitrogen, mg/dl
Serum calcium, mg/dl
Serum phosphorus, mg/dl
Serum alkaline phosphatase, lU/mi
23.4
0.18
75.8
8.74
6.11
77.5
—0.04 0.53
—0.004 0.004
— 1.58 1.89
—0.20 0.08
—0.66 0.29
— 18.4 4.88
0.075
1.0
0.8
2.49
2.27
3.76
>0.9
>0.3
>0.4
<0.02
<0.05
<0.02
a Values are the mean difference 1 SD; analysis by the paired t test.
osmosis water is then allowed to fill the dialysate compart-
ment. A pressure valve and a closed end Hansen connector
at one of the dialysate ports serve to maintain a pressure of
15 pounds/square inch. This process of reverse ultrafiltration
is allowed to continue until no blood or clots are noticed in
the effluent. The flow of water is occluded several times to
allow for a pulse effect.
(4) The arterial and venous headers are reattached and the blood
compartment rinsed again for 5 mm.
(5) The dialyzer is then transferred to sit over a graduated
cylinder and the water content within it expelled with a bulb.
This gives the residual volume of the dialyzer.
(6) The dialyzer is then transferred to a harness where the blood
compartment is hooked to a Y-tubing, with one limb being
attached to a container with 1.5% formaldehyde.
(7) This Y-tubing is part of a vacuum circuit, and the pressure is
momentarily raised to 300 mm Hg by occluding one limb of
the tubing. A sudden fall in pressure or bubbles in the
dialyzer indicates a leak and is an indication to discard the
dialyzer.(8) The limb of the Y-tubing attached to the formaldehyde
container is then unclamped to allow the dialyzer to be filled
with formaldehyde.
(9) A running log is maintained of the number of uses obtained
with each dialyzer and the residual volume at the conclusion
of each dialysis.
Equipment needed
(1) Needed are plumbing and sinks with water outlets connected
to a source of reverse osmosis water at a constant tempera-
ture (36.7 to 37.2° C) and pressure (15 p.s.i.). This is achieved
by using a mixing valve set at a constant temperature and
with the insertion of a pressure regulating valve in the
system.
(2) A system capable of generating negative pressure (for exam-
ple, vacuum pump) of up to 300 mm Hg, which includes (in
parallel) a reservoir of formaldehyde in the circuit, is also
needed.
Appendix B
Costs
No attempt was made to define all components of cost for
single use or for multiple use of dialyzers.
For single use of dialyzers, the cost given is the average cost of
new dialyzers, assuming that the mix of dialyzer types would
have been similar to the mix actually used in the reuse program.
For multiple use of dialyzers, the following were taken into
account: (1) the actual cost of the new artificial kidneys used
during the period of study; (2) personnel costs (the proportion of
time for each individual working with dialyzer reuse was estimat-
ed from time sheets; the personnel cost reflects the time spent in
dialyzer reuse and includes both direct salary and fringe benefits;
(3) costs of rent and utilities (these were derived by assigning to
reuse a proportion of these costs consistent with the proportion
of floor space for the reuse function); and (4) capital costs
(calculated on the basis of the initial capital investment for the
design and construction of the reuse area).
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